Sunesis Pharmaceuticals (NASDAQ:SNSS) and Unum Therapeutics (NASDAQ:UMRX) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, earnings, profitability, risk, dividends, institutional ownership and valuation.
Institutional and Insider Ownership
52.7% of Sunesis Pharmaceuticals shares are held by institutional investors. Comparatively, 40.4% of Unum Therapeutics shares are held by institutional investors. 4.2% of Sunesis Pharmaceuticals shares are held by insiders. Comparatively, 30.8% of Unum Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
Valuation & Earnings
This table compares Sunesis Pharmaceuticals and Unum Therapeutics’ top-line revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Sunesis Pharmaceuticals||$240,000.00||389.57||-$26.61 million||($0.75)||-1.12|
|Unum Therapeutics||$9.73 million||2.54||-$34.53 million||($1.39)||-0.58|
Sunesis Pharmaceuticals has higher earnings, but lower revenue than Unum Therapeutics. Sunesis Pharmaceuticals is trading at a lower price-to-earnings ratio than Unum Therapeutics, indicating that it is currently the more affordable of the two stocks.
Risk & Volatility
Sunesis Pharmaceuticals has a beta of 2.55, suggesting that its share price is 155% more volatile than the S&P 500. Comparatively, Unum Therapeutics has a beta of 0.97, suggesting that its share price is 3% less volatile than the S&P 500.
This is a breakdown of recent ratings for Sunesis Pharmaceuticals and Unum Therapeutics, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Sunesis Pharmaceuticals presently has a consensus target price of $3.75, indicating a potential upside of 346.48%. Unum Therapeutics has a consensus target price of $10.00, indicating a potential upside of 1,142.70%. Given Unum Therapeutics’ stronger consensus rating and higher possible upside, analysts plainly believe Unum Therapeutics is more favorable than Sunesis Pharmaceuticals.
This table compares Sunesis Pharmaceuticals and Unum Therapeutics’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Sunesis Pharmaceuticals Company Profile
Sunesis Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of targeted inhibitors for the treatment of solid and hematologic cancers. Its lead program is vecabrutinib, a non-covalent inhibitor of Bruton's tyrosine kinase (BTK), which is in Phase 1b/2 clinical trial in B-cell malignancies. The company is also developing SNS-510, which is in preclinical pharmacology studies for the treatment of solid tumor and hematologic malignancies; TAK-580, a pan-Raf inhibitor program that is in Phase 1 clinical trial for the treatment of pediatric low-grade glioma; and vosaroxin, a topoisomerase 2 inhibitor, which completed a Phase 3 trial in patients with relapsed or refractory acute myeloid leukemia. It has a collaboration agreement with Biogen Idec MA, Inc. to discover, develop, and commercialize small molecule BTK inhibitors; and license agreement with Takeda Pharmaceutical Company Limited to develop and commercialize preclinical inhibitors of PDK1. Sunesis Pharmaceuticals, Inc. was founded in 1998 and is headquartered in South San Francisco, California.
Unum Therapeutics Company Profile
Unum Therapeutics Inc., a clinical stage biopharmaceutical company, develops and commercializes immunotherapy products designed to harness the power of a patient's immune system to cure cancer. The company's lead product candidate is the ACTR707 used in combination with rituximab, which is in Phase I clinical trials to treat adult patients with relapsed or refractory CD20+ B cell non-Hodgkin lymphoma (r/r NHL). Its product portfolio also includes ACTR087 used in combination with rituximab that is in Phase I clinical trials to treat adult patients with r/r NHL; ACTR087 used in combination with SEA-BCMA, which is in Phase I clinical trials for treating patients with r/r multiple myeloma; ACTR707 used in combination with trastuzumab that is in Phase I clinical trials for treating HER2+ solid tumor cancers; and BOXR1030, which is in pre-clinical stage, targets GPC3, an oncofetal antigen expressed in various tumors, including liver and lung cancers. The company has strategic collaboration with Seattle Genetics, Inc. to identify, research, develop, and commercialize antibody-coupled T cell receptor therapies. Unum Therapeutics Inc. was founded in 2014 and is headquartered in Cambridge, Massachusetts.
Receive News & Ratings for Sunesis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sunesis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.